Robotic Prostatectomy in India
Get Robotic Prostatectomy at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Robotic Prostatectomy in UAE
Robotic Prostatectomy at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Robotic Prostatectomy (Robot-Assisted Radical Prostatectomy, RARP) using the da Vinci Surgical System is the gold-standard minimally invasive treatment for localized and locally advanced prostate cancer, offering superior oncological control, preserved urinary continence, and faster return of erectile function compared to open surgery. Internationally accredited hospitals in India and the UAE report overall biochemical recurrence-free survival rates exceeding 90% at five years for organ-confined disease (pT2), making these destinations increasingly preferred by medical tourists seeking world-class urological oncology care. GAF Healthcare connects international patients with high-volume robotic urology centers in India and the UAE, providing end-to-end coordination — from pre-operative diagnostics to post-operative follow-up — at a fraction of Western costs without compromising clinical outcomes.
Hospital Stay: 2–4 days • Total Stay in Country (Fit-to-Fly): 3–4 weeks (short-haul); 4–6 weeks (long-haul intercontinental flights) • Success Rate: 90–95% biochemical recurrence-free survival at 5 years for organ-confined prostate cancer (pT2); overall perioperative success rate >98%
What Is It?
Prostate cancer is the most commonly diagnosed solid-organ malignancy in men globally, with over 1.4 million new cases recorded annually according to GLOBOCAN 2022 data. The prostate gland — a walnut-sized exocrine gland situated at the base of the bladder surrounding the proximal urethra — plays a central role in semen production. Adenocarcinoma arising from the peripheral zone accounts for approximately 70–75% of prostate cancers and, when confined within the prostatic capsule, is highly amenable to curative surgical extirpation. Left untreated or undertreated, locally advanced disease can invade the seminal vesicles, bladder neck, and neurovascular bundles, ultimately metastasizing to pelvic lymph nodes, bone, and visceral organs, significantly reducing survival and quality of life.
Robot-Assisted Radical Prostatectomy (RARP) represents the current standard of care for surgically resectable prostate cancer. Using the da Vinci Xi or da Vinci SP (Single-Port) robotic platform, the surgeon operates via 4–6 small laparoscopic ports (5–12 mm), manipulating wristed EndoWrist instruments that provide 7 degrees of freedom, 3D stereoscopic high-definition magnification (up to 10×), and tremor filtration — capabilities that are anatomically impossible with conventional laparoscopy or open retropubic surgery. The procedure involves complete excision of the prostate gland, seminal vesicles, and — when oncologically indicated — extended pelvic lymph node dissection (ePLND), followed by a watertight vesicourethral anastomosis (VUA) over a urethral catheter.
The clinical superiority of RARP over open radical prostatectomy (ORP) and conventional laparoscopic prostatectomy is well-documented across multiple dimensions: estimated intraoperative blood loss is typically under 150 mL (versus 500–1,000 mL for ORP), transfusion rates are below 2%, positive surgical margin (PSM) rates for pT2 disease are 6–12% in experienced centers, and the precision of robotic nerve-sparing — utilizing the Veil of Aphrodite technique or Retzius-sparing (posterior approach) RARP — maximizes preservation of the cavernous nerves responsible for erectile function. Post-operative recovery is significantly accelerated, with most patients resuming light activity within 2–3 weeks.
Candidates
• IDEAL CANDIDATES:
• Men diagnosed with clinically localized prostate cancer: cT1c–cT2c, Gleason Grade Group 1–3 (Gleason score 6–7), PSA < 20 ng/mL (intermediate- to favorable-risk per NCCN / EAU risk stratification)
• Locally advanced disease (cT3a–cT3b) in select patients with good performance status where multimodal therapy (RARP + adjuvant radiotherapy) is planned
• Men with high-volume intermediate-risk or high-risk localized disease who have been counseled on the potential need for adjuvant or salvage radiotherapy post-surgery
• Patients who have failed or are ineligible for active surveillance protocols (PSA doubling time < 3 years, upgrading on repeat biopsy)
• Men with a life expectancy of ≥ 10 years and ECOG performance status 0–1
• BMI up to 40 kg/m² (robotic approach is particularly advantageous in obese patients due to improved visualization)
• REQUIRED PRE-OPERATIVE DIAGNOSTICS:
• Serum PSA (total and free/total ratio) and PSA density
• Multi-parametric MRI (mpMRI) of the prostate — 3-Tesla preferred, PI-RADS v2.1 reporting — to assess extracapsular extension, seminal vesicle invasion, and guide nerve-sparing decisions
• MRI/Ultrasound fusion-guided targeted biopsy + systematic 12-core TRUS biopsy with Gleason Grade Group assignment
• PSMA PET/CT (preferred over conventional CT + bone scan for intermediate/high-risk staging): detects nodal and distant metastatic disease with superior sensitivity (86%) and specificity (99%)
• Complete blood count (CBC), comprehensive metabolic panel (CMP), coagulation profile (PT/INR/aPTT)
• Serum testosterone (baseline for post-operative monitoring)
• Cardiac evaluation: 12-lead ECG; ECHO for patients with known cardiac history or ASA Class III
• Pulmonary function tests (PFTs) if significant respiratory comorbidity
• IIEF-5 (International Index of Erectile Function) questionnaire and IPSS (International Prostate Symptom Score) — baseline quality-of-life scoring
• RELATIVE CONTRAINDICATIONS:
• Metastatic prostate cancer (cN1, M1) — systemic therapy is primary; surgery is investigational in the oligometastatic setting
• Prior extensive pelvic surgery or radiation causing dense adhesions (relative; robotic approach may still be feasible)
• Uncorrected coagulopathy or active anticoagulation that cannot be safely bridged
• Severe cardiopulmonary disease precluding prolonged steep Trendelenburg positioning and CO₂ pneumoperitoneum (>15 mmHg insufflation pressure)
• Active urinary tract infection or uncontrolled inflammatory bowel disease
• ASA Class IV or life expectancy < 5–10 years where quality-of-life preservation with watchful waiting/ADT is preferred
Procedure
ROBOTIC PLATFORM OPTIONS:
• da Vinci Xi System (Intuitive Surgical): The most widely deployed platform in India and the UAE. Features a re-architected boom-mounted arm system allowing multi-quadrant access, fluorescence imaging (Firefly) for real-time tissue perfusion assessment, and integration with intraoperative ultrasound. Standard for transperitoneal RARP.
• da Vinci SP (Single-Port): Approved for prostatectomy; all instruments pass through a single 25 mm port, reducing abdominal wall trauma and ideal for patients with prior abdominal surgery. Available at select centers in Dubai and Tier-1 Indian hospitals.
• Hugo RAS System (Medtronic): An emerging platform with open-console architecture; available at pioneering centers in India and increasingly in the UAE, offering comparable oncological outcomes.
SURGICAL APPROACHES:
1. Standard Transperitoneal RARP (Descending / Antegrade Technique): The most common approach. Bladder mobilized, endopelvic fascia incised, dorsal venous complex (DVC) ligated, prostate dissected antegradely. Extended pelvic lymph node dissection (ePLND) is performed for intermediate/high-risk disease (obturator, external iliac, hypogastric nodal packets).
2. Retzius-Sparing (Posterior / Bocciardi) RARP: Preserves the retropubic space (space of Retzius) by approaching the prostate entirely through the pouch of Douglas. Clinical evidence — including the REAP and Retzius-Sparing RCT data — demonstrates significantly faster return of urinary continence (up to 80–90% at 1 month vs. 40–60% with standard approach) with equivalent oncological control for organ-confined disease. Offered at high-volume robotic urology centers in India (e.g., Apollo, Fortis, Manipal) and in Dubai (American Hospital Dubai, Mediclinic City Hospital).
3. Nerve-Sparing RARP — Intrafascial / Interfascial / Extrafascial Technique: The degree of neurovascular bundle (NVB) preservation is individually tailored based on preoperative mpMRI, intraoperative frozen-section analysis, and Epstein criteria. The "Veil of Aphrodite" nerve-sparing maximizes preservation of the lateral NVB. Intraoperative NeuroSAFE (frozen-section NVB margin assessment) is offered at select centers to allow real-time re-resection if required.
4. Hybrid Robotic + Laparoscopic Approach: In select cases with prior inguinal hernia mesh or complex adhesions, a hybrid technique combining robotic dissection with manual laparoscopic assistance is employed.
ADJUNCT TECHNOLOGIES:
• Firefly Fluorescence Imaging: ICG (indocyanine green) injection visualizes lymphatic channels and tissue vascularity intraoperatively — aids ePLND completeness.
• PSMA-Guided Surgery: Investigational integration of PSMA-PET data into intraoperative navigation systems for margin guidance.
• Aquablation (for concurrent BPH): If significant benign prostatic obstruction coexists in a non-oncological context, robotic prostatectomy addresses both pathologies simultaneously.
• Post-operative penile rehabilitation protocol: PDE5 inhibitor therapy (Tadalafil 5 mg daily) commenced within 4–6 weeks of surgery to support cavernous nerve recovery — standard of care at high-volume centers.
Cost of Robotic Prostatectomy: India vs. UAE
The total cost of Robotic Prostatectomy varies substantially between India and the UAE, primarily due to differences in hospital infrastructure costs, labor economics, and healthcare pricing models. Both destinations offer JCI-accredited facilities with equivalent robotic surgical technology (da Vinci Xi/SP) and fellowship-trained urological oncologists — meaning the quality differential is negligible while the price differential is significant. Indian centers typically price RARP at 50–60% below comparable UAE facilities, making India the preferred choice for cost-sensitive patients. The UAE offers premium hotel-style hospital amenities, proximity for Gulf-region patients, and visa-free or visa-on-arrival access for many nationalities. The estimates below reflect all-inclusive packages (surgery, anaesthesia, 3–4 nights hospital stay, standard implants/consumables, pathology, and routine post-operative medications); PSMA PET/CT, pre-operative staging investigations, and adjuvant therapy are billed separately.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $5,000 – $8,500 | ~58% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $12,000 – $20,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-OPERATIVE (Days −14 to −1 before surgery):
• Day −14 to −7: GAF Healthcare coordinates remote review of biopsy pathology slides, mpMRI images, PSMA PET/CT, and PSA kinetics by the treating robotic urologist. A formal opinion letter and surgical plan (approach, nerve-sparing grade, ePLND plan) are issued.
• Day −7: Patient arrives in India or UAE. GAF Healthcare team receives patient at the airport with dedicated transport to partner hotel or hospital guest house.
• Day −5 to −2: Outpatient workup: repeat labs (CBC, CMP, coagulation), anaesthesia fitness assessment (ECG, ECHO if indicated), uroflowmetry, baseline IIEF-5/IPSS scoring, bowel preparation counseling, low-molecular-weight heparin (LMWH) bridging if on anticoagulation.
• Day −1: Pre-operative admission. IV access established, DVT prophylaxis commenced (compression stockings + LMWH), nil per os from midnight, informed consent finalized with surgical and anaesthesia teams.
PHASE 2 — OPERATIVE DAY (Day 0):
• Duration: 2.5–4 hours (robotic console time); total OR time 3–5 hours including docking, ePLND, and anastomosis.
• Anaesthesia: General anaesthesia with endotracheal intubation; steep Trendelenburg position (25–30°); CO₂ pneumoperitoneum at 12–15 mmHg.
• Key intraoperative steps: Port placement → Robot docking → Bladder mobilization → Seminal vesicle dissection → Posterior dissection (or Retzius-sparing entry) → NVB preservation → Apical dissection → DVC ligation → Urethral division → Specimen extraction in an endoscopic retrieval bag → ePLND (if planned) → Vesicourethral anastomosis (Van Velthoven running suture technique) → Drain placement → Catheter confirmation.
• Estimated blood loss: 75–200 mL; transfusion rate < 2%.
• Specimen sent for frozen-section margins and full histopathological analysis (NeuroSAFE if protocol-indicated).
PHASE 3 — IMMEDIATE POST-OPERATIVE RECOVERY (Days 1–5):
• Day 1: Patient typically ambulant (sitting, standing) within 6–12 hours. Clear liquids commenced. IV analgesia transitioned to oral multimodal analgesia (paracetamol + ketorolac + gabapentin). DVT prophylaxis continued.
• Day 1–2: Pelvic drain removed when output < 50 mL/24h and drain creatinine confirms no anastomotic urinary leak.
• Day 2–3: Full liquid/soft diet resumed. Urethral catheter remains in situ.
• Day 2–4: Hospital discharge with urethral catheter in place, leg drainage bag, and written catheter care instructions. Oral antibiotics (ciprofloxacin or nitrofurantoin), LMWH for 2 weeks, constipation prophylaxis.
PHASE 4 — OUTPATIENT RECOVERY (Weeks 1–4):
• Day 7–14: Cystogram (retrograde urethrogram or catheter pouchogram) to confirm anastomotic integrity → Catheter removal (typically Day 10–14). Patient begins pelvic floor physiotherapy (Kegel exercises — minimum 3 sessions/day under physiotherapist guidance arranged by GAF Healthcare).
• Week 2: First post-operative PSA is NOT measured at this stage (PSA nadir takes 4–6 weeks to reach); wound review, continence assessment.
• Week 3–4: Histopathology results reviewed with the surgeon (pT-stage, Gleason Grade Group, surgical margins, lymph node status). Adjuvant treatment planning (radiotherapy/ADT) initiated if pT3 disease, positive margins, or PSA non-nadir.
• Fit-to-Fly milestone: Short-haul flights (< 4 hours): 3 weeks post-operatively, after catheter removal and confirmed healing. Long-haul flights (> 6 hours): 4–6 weeks, with mandatory in-flight LMWH prophylaxis and compression stockings.
PHASE 5 — LONG-TERM FOLLOW-UP (Months 1–60):
• PSA measured at 6 weeks (should be undetectable < 0.1 ng/mL = biochemical complete response).
• Subsequent PSA monitoring: every 3 months (Year 1), every 6 months (Years 2–5), annually thereafter.
• Erectile function rehabilitation: PDE5i (Tadalafil 5 mg daily) for 12–18 months; vacuum erection device if required; specialist sexual medicine review at 6 months.
• Continence: >90% social continence (0–1 pads/day) expected by 3 months; full continence (0 pads) in ~85% by 12 months.
Risks & Considerations
Robotic Prostatectomy carries a well-characterized risk profile that patients must understand before proceeding. Perioperative risks — occurring in < 3% of cases at high-volume centers — include intraoperative hemorrhage requiring conversion to open surgery (< 1%), rectal injury (0.5–1%), ureteral injury (< 0.5%), port-site herniation, and anaesthetic complications including deep vein thrombosis (DVT) or pulmonary embolism (PE), mitigated by standardized LMWH prophylaxis and early ambulation. Post-operative urinary complications include anastomotic leak (1–3%, managed with prolonged catheterization), urethral stricture or bladder neck contracture (2–5%), and urinary tract infection. The two most clinically significant long-term quality-of-life risks are urinary incontinence and erectile dysfunction (ED). Stress urinary incontinence affects approximately 5–20% of patients at 12 months (higher rates in older patients, those with prior TURP, or poor pre-operative continence), and is managed with pelvic floor physiotherapy and, if persistent, surgical options including the AdVance XP male sling or AMS 800 artificial urinary sphincter. Post-prostatectomy ED rates vary widely (15–80%) depending on patient age, pre-operative IIEF-5 score, bilateral vs. unilateral nerve-sparing, and surgeon experience; structured penile rehabilitation with PDE5 inhibitors (Tadalafil), vacuum erection devices, and intracavernosal injection therapy (alprostadil) are employed. Oncologically, positive surgical margins (PSM) occur in 6–20% of cases depending on pathological stage; PSM in pT2 disease indicates need for close PSA surveillance and possible adjuvant radiotherapy. Biochemical recurrence (BCR), defined as PSA > 0.2 ng/mL on two consecutive measurements, occurs in approximately 15–30% of patients at 10 years across all risk groups, and is managed with salvage radiotherapy ± androgen deprivation therapy (ADT). Patients with pre-existing cardiovascular disease, diabetes, or obesity carry higher risks of wound complications, prolonged ileus, and thromboembolic events — all of which are assessed and risk-stratified during the pre-anaesthesia evaluation. GAF Healthcare's partner hospitals conduct formal Charlson Comorbidity Index (CCI) and ASA Physical Status scoring for every patient to individualize perioperative risk.
Top Hospitals for Robotic Prostatectomy
Frequently Asked Questions — Robotic Prostatectomy
The all-inclusive cost of Robotic Prostatectomy (RARP using the da Vinci Xi System) at JCI- and NABH-accredited hospitals in India typically ranges from USD 5,000 to USD 8,500. This package generally covers the robotic surgical procedure (including consumables and EndoWrist instruments), general anaesthesia, a 3–4 night hospital stay in a private room, standard post-operative medications, histopathology/frozen-section analysis, and the operating surgeon's fee. Pre-operative staging investigations (PSMA PET/CT: approximately USD 400–600; mpMRI prostate: USD 150–300) are usually billed separately. In the UAE — specifically at JCI- and DHA-accredited hospitals in Dubai and Abu Dhabi — the equivalent procedure is priced between USD 12,000 and USD 20,000, reflecting higher facility and operational costs. India therefore offers a cost saving of approximately 50–60% versus the UAE for the same robotic platform, equivalent surgical expertise, and accreditation standards. GAF Healthcare provides transparent, itemized cost estimates for both destinations before any commitment, with no hidden fees.
Following Robotic Prostatectomy, the minimum recommended in-country stay before any international flight is 3 weeks for short-haul travel (under 4 hours flight duration) and 4–6 weeks for long-haul intercontinental flights. The key clinical milestones that must be achieved before clearance for air travel include: (1) hospital discharge with a functioning urethral catheter (typically Day 2–4 post-surgery); (2) catheter removal after confirmed anastomotic integrity on cystogram (typically Day 10–14); (3) wound healing and absence of infection or anastomotic leak; (4) surgeon review of final histopathology results and formulation of any adjuvant treatment plan. Air travel — particularly long-haul — poses an elevated risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) in the early post-prostatectomy period due to prolonged immobility and the prothrombotic surgical state. All patients traveling by air post-operatively must wear graduated compression stockings and self-administer low-molecular-weight heparin (LMWH, e.g., Enoxaparin 40 mg subcutaneously) on the day of the flight, as prescribed by the surgeon. GAF Healthcare's Patient Care Manager coordinates the formal fit-to-fly certification letter issued by the treating urologist, which is required by most airlines for post-surgical passengers.
The success of Robotic Prostatectomy is measured across three inter-related oncological and functional dimensions. Oncologically, the gold-standard metric is biochemical recurrence-free survival (bRFS), defined as maintaining an undetectable PSA (< 0.1 ng/mL) after surgery without additional treatment. At high-volume robotic urology centers in India and the UAE, the 5-year bRFS rate exceeds 90% for organ-confined prostate cancer (pathological stage pT2, Gleason Grade Group 1–3). For locally advanced disease (pT3), 5-year bRFS is approximately 70–80% when combined with adjuvant or early salvage radiotherapy. Functionally, urinary continence recovery — defined as using zero to one safety pad per day — is achieved in approximately 85–90% of patients by 12 months post-surgery in nerve-sparing cases performed at experienced centers. The Retzius-sparing (posterior approach) RARP technique significantly accelerates continence recovery, with 80–90% of patients achieving social continence within 4 weeks. Erectile function recovery (return of spontaneous erections sufficient for penetration) is achieved in 50–80% of men under age 65 who undergo bilateral nerve-sparing RARP and adhere to a structured penile rehabilitation protocol (daily PDE5 inhibitor therapy) — recovery continues for up to 18–24 months post-surgery. The perioperative safety rate (absence of major complications requiring re-intervention) exceeds 97–98% at JCI-accredited centers. GAF Healthcare selectively partners only with hospitals where the treating robotic urologist has performed a minimum of 500 documented RARP procedures, as surgical volume is the single strongest predictor of positive surgical margin rates, continence outcomes, and nerve-sparing success.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides a fully integrated medical tourism coordination service that removes every non-clinical barrier for international patients traveling to India or the UAE for Robotic Prostatectomy.
INDIA — VISA & ENTRY:
• e-Medical Visa (eMV) application is managed entirely by the GAF Healthcare concierge team. The eMV is issued within 3–5 business days for most nationalities, allows two companion attendants on a Medical Attendant Visa (eMAV), and permits multiple entries valid for 60 days. The invitation/reference letter from the treating Indian hospital — required for the eMV application — is coordinated by GAF Healthcare at no additional charge.
• GAF Healthcare registers all foreign patients with India's Foreigner Regional Registration Office (FRRO) digitally where required.
UAE (DUBAI / ABU DHABI) — VISA & ENTRY:
• Citizens of 49+ countries (including all EU, UK, USA, Canada, Australia) receive visa-on-arrival or visa-free entry to the UAE for 30–90 days.
• For nationalities requiring prior visa, GAF Healthcare facilitates the UAE Medical Treatment Visa application through the Federal Authority for Identity and Citizenship (ICA), coordinated in partnership with the receiving JCI/DHA-accredited hospital.
• Dubai Health Authority (DHA) and Department of Health Abu Dhabi (DoH) patient authorization paperwork is handled by the GAF Healthcare UAE operations team.
AIRPORT & GROUND LOGISTICS:
• Dedicated airport meet-and-greet service with patient name-board pickup, wheelchair assistance (if required), and direct transfer in an air-conditioned private vehicle to the hospital or partner accommodation.
• GAF Healthcare maintains preferred-rate agreements with serviced apartments and hotel guest houses within 2 km of partner hospitals in Mumbai, Delhi-NCR, Chennai, Bengaluru, Dubai, and Abu Dhabi — providing comfortable, hygienic accommodation for one or two patient attendants at INR 2,500–5,000/night (India) or AED 250–500/night (UAE).
MEDICAL COORDINATION:
• A dedicated GAF Healthcare Patient Care Manager (PCM) is assigned from the first inquiry to the day of departure. The PCM coordinates all appointment scheduling, diagnostic sequencing, operating theatre booking, and discharge planning.
• Certified medical interpreters are available in Arabic, Russian, French, Swahili, Bangla, and other languages for in-hospital consultations and consent discussions.
• Digital health record transfer: all pre-operative imaging (DICOM files), biopsy reports, and lab results are uploaded to a secure portal and reviewed by the treating urologist before patient arrival, eliminating redundant investigations.
• Telemedicine follow-up: post-discharge PSA results, continence progress, and pathology review are conducted via scheduled video consultations with the treating surgeon, facilitated through the GAF Healthcare patient portal.